AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
BioSpace23h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Benzinga.com17d
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment ... While Bristol-Myers Squibb’s recent ...
Newsday18d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for ... independent research team and shared by Bristol Myers Squibb showed the likelihood of continuing treatment. After six months, 36 said they ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Business Insider7d
Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia ... stocks on TipRanks >> Read More on BMY: ...
Seeking Alpha17d
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy ... discontinuation rates due to treatment-related or treatment-emergent adverse events (TEAE) stood at 11% and ...
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
Business Wire21d
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol ... Schizophrenia – A Network Meta-Analysis Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S. A full list of Bristol Myers ...
Yahoo Finance14d
Bristol-Myers Squibb Company (BMY)
2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults PRINCETON, N.J., September 15, 2024--Bristol Myers Squibb ...
The Associated Press on MSN18d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for a year improved ... conducted by an independent research team and shared by ...
Joplin Globe21d
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and ...